Navigation Links
Favrille Announces $21.1 Million Registered Direct Offering
Date:11/2/2007

EF="http://www.sec.gov" target="_new">http://www.sec.gov or from Lazard Capital Markets LLC at 30 Rockefeller Plaza, 60th Floor, New York, NY, 10020.

About Favrille, Inc.

Favrille, Inc. is a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. The Company's lead product candidate, FavId, is based upon unique genetic information extracted from a patient's tumor. FavId is currently under investigation in a pivotal Phase 3 clinical trial for patients with follicular B-cell non-Hodgkin's lymphoma (NHL) and Phase 2 clinical trials in other B-cell NHL indications. The Company is developing additional applications based on its immunotherapy expertise and proprietary cost-effective manufacturing technology, including a second product candidate, FAV-201, for the treatment of cutaneous T-cell lymphoma. To receive additional information on the Company, please visit our website at http://www.favrille.com. Information on our website does not, however, form a part of this press release.

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected closing date for the financing, Favrille's product candidates, proprietary technologies and research programs. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Favrille's actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to whether the offering will close when expected or at all; progress and timing of clinical trials for FavId, including difficulties or delays in development, testing, ma
'/>"/>

SOURCE Favrille, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... with State Biotech Leaders to Develop Blueprint ... Development while Boosting Rhode Island,s Growing Biotech ... R.I., Dec. 14 Several of ... medicine and biotechnology gathered today at Brown ... importance of medical innovation in Rhode Island ...
(Date:12/14/2009)... -- Lionbridge (Nasdaq: LIOX ) today ... three-year master services agreement with a multi-billion ... that serve patients in approximately 100 countries. ... sole provider for translation of the company,s ... human resources, legal, and corporate communications information. ...
(Date:12/14/2009)... delivery of Brookfield Engineering’s Powder Flow Tester – helping Brookfield ... smaller footprint and more compact design. , ... ... a US-based thermoforming company, has completed the delivery of Brookfield ... metal to a plastic enclosure with a smaller footprint and ...
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
Breaking Biology Technology:Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 2Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 3Former Congressman Dick Gephardt Brings National Spotlight to Rhode Island with 'Best and Brightest Forum on Medical Innovation' 4Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 2Multi-Billion Dollar Biotech Firm Chooses Lionbridge as Exclusive Translation Provider with Three-Year Master Services Agreement 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3
... human immune system isnt ready for a war. , ... illness, but they take time to work. A new ... Foundation (OMRF) and Emory University stands to revolutionize the ... Nature, the researchers describe a method that can identify ...
... active first quarter 2008 stock ... repurchase program, BOSTON, April ... medical image and information management,solutions, today reported unaudited financial results for the ... ), Q1 Financial Highlights, Revenue: Total revenues for ...
... a New Step in the Company,s Global Branding ... (Nasdaq:,SIAL) today announced the full integration of its ... effective May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., "We ... products and,services," said Josef Zihlmann, Global Vice President ...
Other Biology Technology:The most natural drug 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 3AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 4AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 5AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 6AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 7AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 8AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 9AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 10AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 11Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
(Date:12/14/2009)... (INTA-CSIC) has shown that hydrogen cyanide, urea and other ... basic biological molecules can be obtained from the salt ... published in the journal Chemistry & Biodiversity , ... Earth. , "We have shown that when Prussian blue ... a substance that could have played a fundamental role ...
(Date:12/14/2009)... As good as laparoscopy is in preventing some of ... have drawbacks, including reduced blood flow and organ dysfunction. Laparoscopy ... small incisions. , By adding another ... area during laparoscopy, researchers at Duke University Medical Center have ... surgery. , The gas ethyl nitrite (ENO) helped to ...
(Date:12/13/2009)... that are associated with the health of the human ... scientists from 63 centres in Europe and Australia sheds ... , The new findings provide hope for better treatment ... and asthma. In the past it has been difficult ... affect the health of the lung are not completely ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2Gas improves blood flow and organ status during minimally invasive surgery 2New genes for lung disease discovered 2Good Samaritan Hospital Dayton Rated 231 in Ohio for Vascular Surgery 3B 231 in Dayton for Joint Replacement 59367 1Good Samaritan Hospital Dayton Rated 231 in Ohio for Vascular Surgery 3B 231 in Dayton for Joint Replacement 59367 2Good Samaritan Hospital Dayton Rated 231 in Ohio for Vascular Surgery 3B 231 in Dayton for Joint Replacement 59367 3New Palliative Medicine Hotline Reaches California 59363 1New Palliative Medicine Hotline Reaches California 59363 2New Palliative Medicine Hotline Reaches California 59363 3Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 1Recently Approved Onglyza Is Covered by 44 Percent of Commercial Health Plans But Less Than One Percent of Medicare Plans for The Treatment of Type 2 14449 2
... of adults aged 20 and over, researchers at Tufts University ... levels in individuals who have a combination of vitamin B12 ... are also vitamin B12 deficient but have normal folate levels. ... enzymes that contain vitamin B12, accumulate in the blood in ...
... laboratory tool for measuring pharmacological activity of biological substances ... by a new miniaturized bioassay that will be faster, ... new technology developed by Singapores Institute of Bioengineering and ... DropArray, slashes the time needed to run certain lab ...
... muscle. Sometimes one sudden, inconsiderate movement does the job. ... as other tissues such as bone. Researchers of the ... and the Harefield Heart Science Centre of Imperial College ... muscle regenerate and protects it from atrophy. In this ...
Other Biology News:Vitamin B-12 function may be diminished by excessive folate 2Cheaper drugs now closer to realization with new DropArray technology 2Cheaper drugs now closer to realization with new DropArray technology 3An ambulance man for muscle damage 2
Bovine Coronary Artery Smooth Muscle Cells (BCASMC) (>500,000 cells)...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Bovine Aortic Smooth Muscle Cells (BAOSMC) (>500,000 cells)...
Bovine Brain Microvascular Endothelial Cells (BBMVEC) (>500,000 cells)...
Biology Products: